Trials / Completed
CompletedNCT03108833
A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism
A Phase IIa Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Pulmonary Embolism
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is being conducted to assess the efficacy and safety of recombinant Human Prourokinase in the acute pulmonary embolism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant Human Prourokinase | The drug is used for intravenous thrombolysis therapy |
| DRUG | Alteplase | The drug is used for intravenous thrombolysis therapy |
Timeline
- Start date
- 2017-06-06
- Primary completion
- 2019-12-19
- Completion
- 2019-12-19
- First posted
- 2017-04-11
- Last updated
- 2021-03-18
Locations
18 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03108833. Inclusion in this directory is not an endorsement.